

New Approaches to Modulating Blood Coagulation

Published date: May 28, 2013

Technology description

Potential as Coagulation-inhibiting Medical Agent

Patients suffering from these symptoms and diseases are given coagulation-inhibiting substances to stimulate the body' s own coagulation-inhibiting enzymes, such as antithrombin. Various anticoagulants, such as heparin, are used in prophylaxis and therapy as well as during operations in order to inhibit blood coagulation. As the agents used so far have a number of side effects, alternative antithrombin co-factors are in great demand in the pharmaceutical and medical sector. Scientists of the Institute of Nanotechnology (INT), in cooperation with the University of Murcia, Spain, have now found a new candidate agent that may possibly be better suited for application to diabetes patients and persons suffering from sugar allergy.

Application area

Anti-coagulants have many therapeutic applications. They are applied to patients having a disposition to the formation of blood clots (thrombus) and for the treatment of thrombosis and embolism in arteries or veins. The most frequent reasons for a therapeutic anti-coagulation are cardiac arrhythmias associated with an increased risk of embolism and thrombosis (mostly of the leg veins), hemophilia, pulmonary embolism, and infarction.

Advantages

The new control structure, D-myo-inositol 3,4,5,6-tetrakiphosphate, has a high coagulation-inhibiting potential and might be suitable for use as an anti-coagulant. The natural substance binds with nanomolar affinity to antithrombin and acts as a heparin co-factor. Contrary to conventional heparin analogs, this substance is not based on polysaccharides and does not exhibit any toxic properties in the model. First tests revealed an improvement of coagulation-inhibiting functions for patients with antithrombin deficiency and bad heparin uptake.

Institution

Karlsruhe Institute of Technology

联系我们



叶先生

电话: 021-65679356 手机: 13414935137 邮箱: yeyingsheng@zf-ym.com